GlassScriptPhysician profile
Aaron D Swedberg
NPI 1225426281
$5,101.86
in general payments reported to CMS, 2019-2025
23 companies · $698 in 2025
The $698 reported for 2025 was more than what 77% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,307 · 2022: $1,026 · 2023: $1,096 · 2024: $975 · 2025: $698.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,769.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,769.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,009.24 | 2021-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Novartis Pharmaceuticals Corporation | $763.29 | 2021-2025 | |
| Pfizer INC. | $540.12 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $503.46 | 2021-2024 | Xarelto |
| Abbvie INC. | $500.66 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $391.27 | 2021-2024 | Farxiga |
| Electromed, INC. | $290.29 | 2021-2024 | Smartvest |
| Merck Sharp & Dohme LLC | $222.18 | 2021-2024 | Dificid, Verquvo, Zerbaxa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $152.95 | 2022-2025 | Lifevest |
| Paratek Pharmaceuticals, INC. | $148.19 | 2021-2023 | Nuzyra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $132.95 | 2022-2025 | Xifaxan |
| Gilead Sciences, INC. | $85.77 | 2022-2023 | Veklury |
| Alexion Pharmaceuticals, INC. | $70.24 | 2021-2023 | Ultomiris |
| Novo Nordisk INC | $54.70 | 2024 | Rybelsus, Ozempic |
| Melinta Therapeutics, LLC | $47.37 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nabriva Therapeutics, Plc | $41.40 | 2021 | |
| Abbott Laboratories | $23.68 | 2022 | |
| Medtronic, INC. | $22.96 | 2021 | |
| Shionogi INC | $21.45 | 2023 | Fetroja |
| Insmed, INC. | $21.44 | 2023 | Arikayce |
| Bayer Healthcare Pharmaceuticals INC. | $20.04 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $19.21 | 2025 | Eliquis |
| Alnylam Pharmaceuticals INC. | $19.00 | 2023 | Givlaari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Swedberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.